 Though most ruthenium complexes are only in the beginning stages of the approval process for anti-cancer drugs, many of their properties may give them advantages over many platinum-based drugs now in use.Ruthenium complexes typically adopt oxidation states II, III, and IV.The geometry assumed by most ruthenium complexes is hexacoordinate, and octahedral, which differs from the square planar molecular geometry typical for platinum(II).